Prophylaxis News and Research

RSS

World leaders address country ownership, accountability, women at MDG summit

At the U.N. Summit on the Millennium Development Goals (MDGs) on Tuesday African leaders said "they could do more to meet U.N. goals to slash extreme poverty and urged stronger leadership among developing countries to tackle hunger and disease and attract investment," Reuters reports in an article that examines the leaders' call for African nations to take greater ownership over their development.

23 Sep 2010

New anti-pathogenic drugs render MRSA harmless without killing bacteria

Menachem Shoham, PhD, associate professor and researcher in the department of biochemistry at the Case Western Reserve University School of Medicine, has identified new anti-pathogenic drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) harmless by preventing the production of toxins that cause disease.

17 Sep 2010

ViroPharma presents Phase 1 study data of VP20621 at ICAAC 2010

ViroPharma Incorporated today announced the presentation of data from its Phase 1 study of VP20621 (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections, a common and dangerous gastrointestinal infection typically occurring in older adults after use of antibiotic medications.

16 Sep 2010

RAB-1 monoclonal antibody study shows positive result for rabies

With the potential to save tens of thousands of lives each year, a new cost-effective rabies therapy developed by MassBiologics at the University of Massachusetts and the Serum Institute of India took an important step forward with positive results from a Phase 1 study. The recently completed study showed that a new monoclonal antibody (RAB-1) resulted in protective antibody levels in the serum of treated subjects equal to the current standard of treatment, which is often not available in the areas of the world hit hardest by rabies.

15 Sep 2010

$Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy$

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

15 Sep 2010

NUH receives DSRB approval for new comparative study with TIGR Matrix Surgical Mesh

Novus Scientific Pte. Ltd today announced that the National University Hospital (NUH), Singapore has received Domain Specific Review Board (DSRB i.e. IRB equivalent) provisional approval for a new study: Abdominal Wall Closure After Lipectomy, TRAM/DIEP Flap - Comparison of TIGR (100% Resorbable) vs Polypropylene (Permanent) Mesh.

13 Sep 2010

Octapharma sponsors symposium on inhibitors in Haemophilia A

In a showing of its continued commitment to eradicating today's major complication in the treatment of haemophilia with FVIII concentrates − i.e. anti-FVIII neutralising antibodies − Octapharma AG recently sponsored a symposium, "Inhibitors in Haemophilia A: Prevention, Current Management and Personalised Therapy Perspectives", on July 13, 2010 at the World Federation of Haemophilia's (WFH's) yearly congress.

13 Sep 2010

AVAC welcomes new Global HIV Vaccine Enterprise Scientific Strategic Plan

AVAC welcomes the new Global HIV Vaccine Enterprise Scientific Strategic Plan, released today, as a critical document that the field must implement as part of ongoing efforts to improve coordination, efficiency and transparency to quickly capitalize on recent advances in AIDS vaccine research.

8 Sep 2010

American features series on HIV/AIDS: Prevention Strategies, MSM, Idus

A Scientific American series examines how recent scientific advances will guide future efforts to thwart HIV/AIDS and also looks at the epidemic among men who have sex with men (MSM) and injecting drug users (IDUs).

27 Aug 2010

Quark enters licensing option agreement with Novartis for p53 temporary inhibitor siRNA drug QPI-1002

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.

18 Aug 2010

Belatacept study data to be presented at 23rd International Congress of The Transplantation Society

Bristol-Myers Squibb Company announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of seven oral clinical presentations related to kidney transplantation at the 23rd International Congress of The Transplantation Society, being held August 15-19, 2010, in Vancouver, British Columbia, Canada. In total, 18 abstracts from company-sponsored studies will be presented during the congress.

16 Aug 2010

Needle-free natural vaccine against malaria: Research

A study published in the journal Science Translational Medicine proposes that preventative treatment with affordable and safe antibiotics in people living in areas with intense malaria transmission has the potential to act as a 'needle-free' natural vaccine against malaria and may likely provide an additional valuable tool for controlling and/or eliminating malaria in resource-poor settings.

12 Aug 2010

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

11 Aug 2010

FDA approves Pfizer's Prefilled Dual-Chamber Syringe for XYNTHA administration in hemophilia A patients

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and for surgical prophylaxis in patients with hemophilia A.

9 Aug 2010

ViroPharma announces data on safety, efficacy of Cinryze to treat acute angioedema attacks

ViroPharma Incorporated today announced that data from Phase 3 studies of Cinryze (C1 esterase inhibitor [human]) have been published in the August 5, 2010 issue of the New England Journal of Medicine. The paper entitled Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema by Dr. Bruce L. Zuraw et al. describes the safety and efficacy of Cinryze in treating and preventing attacks of hereditary angioedema. Cinryze is the first and only FDA-approved C1 esterase inhibitor therapy indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), a rare, debilitating and potentially fatal disease; it is not approved by the FDA to treat acute angioedema attacks.

6 Aug 2010

Rush University Medical Center first to receive Octapharma grant under anniversary program

Octapharma USA today announced the first grant recipient of the Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center. The Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

3 Aug 2010

Allergan second-quarter diluted EPS increases to $0.78

Allergan, Inc. today announced operating results for the quarter ended June 30, 2010. Allergan also announced that its Board of Directors has declared a second quarter dividend of $0.05 per share, payable on September 7, 2010 to stockholders of record on August 17, 2010.

3 Aug 2010

ViroPharma second-quarter net sales increase 33% to $109.0 million

ViroPharma Incorporated reported today its financial results for the second quarter ended June 30, 2010.

28 Jul 2010

AIDS 2010: Obama, Clinton vow U.S. support to global fight against HIV/AIDS

During the closing ceremonies of the International AIDS Conference-AIDS 2010, President Barack Obama "on Friday pledged to redouble efforts to fight HIV and AIDS through his Global Health Initiative, despite dealing with economic hard times in the wake of a global recession," Reuters reports. According to the news service, "Obama and his Secretary of State Hillary Clinton said their focus was on a broad, sustainable and effective approach to the global epidemic" (Kelland, 7/23).

26 Jul 2010

AVAC releases GPP Guidelines at International AIDS Conference

The draft second edition of The Good Participatory Practice Guidelines for Biomedical HIV Prevention Trials were released yesterday at the International AIDS Conference in Vienna by AVAC. The GPP Guidelines aim to provide trial funders, sponsors, and implementers with systematic guidance on how to effectively work with a range of stakeholders as they design and conduct biomedical HIV prevention trials.

23 Jul 2010